BUDGET IMPACT ANALYSIS OF VENETOCLAX COMBINATION THERAPIES FOR THE TREATMENT OF NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS WHO ARE AGED 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
Conferences
Xu, Y; Nguyen, J; Miu, K; Lin, C-W; Montez, M; Chai, X; Chen, X; Leblanc, T
Published in: VALUE IN HEALTH
July 2025
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
VALUE IN HEALTH
EISSN
1524-4733
ISSN
1098-3015
Publication Date
July 2025
Volume
28
Issue
6
Start / End Page
S139 / S139
Related Subject Headings
- Health Policy & Services
- 4407 Policy and administration
- 4203 Health services and systems
- 3801 Applied economics
Citation
APA
Chicago
ICMJE
MLA
NLM
Xu, Y., Nguyen, J., Miu, K., Lin, C.-W., Montez, M., Chai, X., … Leblanc, T. (2025). BUDGET IMPACT ANALYSIS OF VENETOCLAX COMBINATION THERAPIES FOR THE TREATMENT OF NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS WHO ARE AGED 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY. In VALUE IN HEALTH (Vol. 28, pp. S139–S139).
Xu, Yanqing, Janet Nguyen, Kaylee Miu, Chia-Wei Lin, Melissa Montez, Xinglei Chai, Xin Chen, and Thomas Leblanc. “BUDGET IMPACT ANALYSIS OF VENETOCLAX COMBINATION THERAPIES FOR THE TREATMENT OF NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS WHO ARE AGED 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY.” In VALUE IN HEALTH, 28:S139–S139, 2025.
Xu Y, Nguyen J, Miu K, Lin C-W, Montez M, Chai X, et al. BUDGET IMPACT ANALYSIS OF VENETOCLAX COMBINATION THERAPIES FOR THE TREATMENT OF NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS WHO ARE AGED 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY. In: VALUE IN HEALTH. 2025. p. S139–S139.
Xu, Yanqing, et al. “BUDGET IMPACT ANALYSIS OF VENETOCLAX COMBINATION THERAPIES FOR THE TREATMENT OF NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS WHO ARE AGED 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY.” VALUE IN HEALTH, vol. 28, no. 6, 2025, pp. S139–S139.
Xu Y, Nguyen J, Miu K, Lin C-W, Montez M, Chai X, Chen X, Leblanc T. BUDGET IMPACT ANALYSIS OF VENETOCLAX COMBINATION THERAPIES FOR THE TREATMENT OF NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS WHO ARE AGED 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY. VALUE IN HEALTH. 2025. p. S139–S139.
Published In
VALUE IN HEALTH
EISSN
1524-4733
ISSN
1098-3015
Publication Date
July 2025
Volume
28
Issue
6
Start / End Page
S139 / S139
Related Subject Headings
- Health Policy & Services
- 4407 Policy and administration
- 4203 Health services and systems
- 3801 Applied economics